Allogene Therapeutics Inc Revenue Growth Rates (ALLO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Allogene Therapeutics Inc   (NASDAQ: ALLO)
 

ALLO's Revenue Growth by Quarter and Year

Allogene Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ALLO/growth
https://api.csimarket.com/api/v1/companies/ALLO/fundamentals
https://api.csimarket.com/api/v1/companies/ALLO/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ALLO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.80
2nd Quarter June 5.34
1st Quarter March 0.80
FY 6.94

ALLOs Annual Revenue
Allogene Therapeutics Inc 's Revenue in the fiscal year 2025 $ 2.60 millions
Allogene Therapeutics Inc 's Revenue in the fiscal year 2024 $ 0.02 millions
Allogene Therapeutics Inc 's Revenue in the fiscal year 2023 $ 0.10 millions
Allogene Therapeutics Inc 's Revenue in the fiscal year 2022 $ 0.16 millions
Allogene Therapeutics Inc 's Revenue in the fiscal year 2021 $ 38.49 millions




ALLO Revenue third quarter 2026 Y/Y Growth Comment
Allogene Therapeutics Inc reported Revenue increase of 14.29% year on year in the third quarter 2026, to $ 0.80 millions, this is lower than Allogene Therapeutics Inc 's recent average Revenue surge of 127.08%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Revenue growth. While Allogene Therapeutics Inc ' s Revenue growth of 14.29% ranks overall at the positon no. 75 in the third quarter 2026.


ALLO Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 14.29 %
2nd Quarter June 567.5 %
1st Quarter March 166.67 %
FY   -

Financial Statements
Allogene Therapeutics Inc 's third quarter 2026 Revenue $ 0.80 millions ALLO's Income Statement
Allogene Therapeutics Inc 's third quarter 2025 Revenue $ 0.70 millions Quarterly ALLO's Income Statement


ALLO Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -85.02 %
2nd Quarter June 567.5 %
1st Quarter March 0 %
FY (Year on Year)   -


Back to ALLO Growth rate Comparisons >> Back to ALLO Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #25
Overall #75

Revenue Y/Y Growth Statistics
High Average Low
1263.64 % 127.08 % -100 %
(Jun 30 2026)   (Dec 31 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #25
Overall #75
Revenue Y/Y Growth Statistics
High Average Low
1263.64 % 127.08 % -100 %
(Jun 30 2026)   (Dec 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Allogene Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
567.5 % 29.58 % -100 %
(Jun 30 2026)  


ALLO's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Allogene Therapeutics Inc disclosed fall in Revenue from the second quarter by -85.02% to $ 0.80 millions, from $ 5.34 millions achived in the previous reporting period.

But that's not important problem, as Allogene Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Allogene Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 44.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #17
Overall #44
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #17
Overall #44
Revenue Q/Q Growth Statistics
High Average Low
567.5 % 29.58 % -100 %
(Jun 30 2026)  


ALLO's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Allogene Therapeutics Inc disclosed fall in Revenue from the second quarter by -85.02% to $ 0.80 millions, from $ 5.34 millions achived in the previous reporting period.

But that's not important problem, as Allogene Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Allogene Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 44.


Allogene Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.00
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) -
Seq. Revenue Growth (TTM) Overall Ranking #


Cumulative Revenue growth Comment
In the Jun 30 2026 period, Allogene Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Allogene Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Jun 30 2026 period, Allogene Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Allogene Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ALLO's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
The Oncology Institute Inc 24.31%$ 24.313 millions
Vanda Pharmaceuticals Inc 24.10%$ 24.098 millions
Mannkind Corporation24.04%$ 24.035 millions
Castle Biosciences Inc 23.90%$ 23.901 millions
Coherus Oncology inc 23.36%$ 23.360 millions
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Protalix Biotherapeutics inc 22.82%$ 22.822 millions
Capsovision Inc 22.44%$ 22.443 millions
Veracyte Inc 22.10%$ 22.105 millions
Radnet Inc 22.07%$ 22.068 millions
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Anteris Technologies Global Corp 20.98%$ 20.979 millions
Trisalus Life Sciences Inc 20.81%$ 20.807 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Alpha Pro Tech Ltd 19.73%$ 19.729 millions
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
Ardelyx inc 15.70%$ 15.704 millions


About Allogene Therapeutics Inc Revenue Growth Rates (ALLO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Allogene Therapeutics Inc (CIK 1737287).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-071191
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Allogene Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.